NCT03651544View on ClinicalTrials.gov

The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 15, 2018

Primary Completion Date

December 24, 2018

Study Completion Date

March 14, 2019

Conditions
Influenza A Virus InfectionInfluenza AInfluenza EpidemicInfluenza H5N1
Interventions
BIOLOGICAL

GamFluVac

1 dose (0,5 ml)

Trial Locations (1)

141306

"Federal state budgetary institution Main military clinical hospital named after academician N. N. Burdenko of the Ministry of Defence of the Russian Federation", Moscow

All Listed Sponsors
lead

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER

NCT03651544 - The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac | Biotech Hunter | Biotech Hunter